Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease
- PMID: 33546130
- PMCID: PMC7913263
- DOI: 10.3390/nu13020494
Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease
Abstract
Non-alcoholic fatty liver disease (NAFLD), which is emerging as a major public health issue worldwide, is characterized by a wide spectrum of liver disorders, ranging from simple fat accumulation in hepatocytes, also known as steatosis, to non-alcoholic steatohepatitis (NASH) and cirrhosis. At present, the pharmacological treatment of NAFLD is still debated and dietary strategies for the prevention and the treatment of this condition are strongly considered. Polyphenols are a group of plant-derived compounds whose anti-inflammatory and antioxidant properties are associated with a low prevalence of metabolic diseases, including obesity, hypertension, and insulin resistance. Since inflammation and oxidative stress are the main risk factors involved in the pathogenesis of NAFLD, recent studies suggest that the consumption of polyphenol-rich diets is involved in the prevention and treatment of NAFLD. However, few clinical trials are available on human subjects with NAFLD. Here, we reviewed the emerging existing evidence on the potential use of polyphenols to treat NAFLD. After introducing the physiopathology of NAFLD, we focused on the most investigated phenolic compounds in the setting of NAFLD and described their potential benefits, starting from basic science studies to animal models and human trials.
Keywords: antioxidant; food; insulin-resistance; steatohepatitis; steatosis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.Liver Int. 2016 Jan;36(1):5-20. doi: 10.1111/liv.12975. Epub 2015 Nov 5. Liver Int. 2016. PMID: 26436447 Review.
-
The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.Br J Clin Pharmacol. 2017 Jan;83(1):88-95. doi: 10.1111/bcp.12899. Epub 2016 Mar 4. Br J Clin Pharmacol. 2017. PMID: 26852185 Free PMC article. Review.
-
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.Front Immunol. 2022 Sep 9;13:949746. doi: 10.3389/fimmu.2022.949746. eCollection 2022. Front Immunol. 2022. PMID: 36159792 Free PMC article.
-
The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling.Biomed Pharmacother. 2020 Nov;131:110785. doi: 10.1016/j.biopha.2020.110785. Epub 2020 Sep 29. Biomed Pharmacother. 2020. PMID: 33152943 Review.
-
Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.Curr Pharm Des. 2017;23(7):969-982. doi: 10.2174/1381612822666161010115235. Curr Pharm Des. 2017. PMID: 27748192 Review.
Cited by
-
Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay.Nutrients. 2022 Dec 15;14(24):5323. doi: 10.3390/nu14245323. Nutrients. 2022. PMID: 36558483 Free PMC article. Review.
-
Polyphenol Profile, Antioxidant Activity, and Hypolipidemic Effect of Longan Byproducts.Molecules. 2023 Feb 23;28(5):2083. doi: 10.3390/molecules28052083. Molecules. 2023. PMID: 36903329 Free PMC article.
-
Effect of Nut Consumption on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Nutrients. 2023 May 19;15(10):2394. doi: 10.3390/nu15102394. Nutrients. 2023. PMID: 37242277 Free PMC article.
-
Polyphenol Intervention Ameliorates Non-Alcoholic Fatty Liver Disease: An Updated Comprehensive Systematic Review.Nutrients. 2024 Nov 29;16(23):4150. doi: 10.3390/nu16234150. Nutrients. 2024. PMID: 39683546 Free PMC article.
-
Silibinin's role in counteracting neuronal apoptosis and synaptic dysfunction in Alzheimer's disease models.Apoptosis. 2025 Apr;30(3-4):861-879. doi: 10.1007/s10495-024-02073-x. Epub 2025 Jan 20. Apoptosis. 2025. PMID: 39833635
References
-
- European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64:1388–1402. doi: 10.1016/j.jhep.2015.11.004. - DOI - PubMed
-
- Kleiner D.E., Brunt E.M., Wilson L.A., Behling C., Guy C., Contos M., Cummings O., Yeh M., Gill R., Chalasani N., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity with Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw. Open. 2019;2:e1912565. doi: 10.1001/jamanetworkopen.2019.12565. - DOI - PMC - PubMed
-
- Addolorato G., Abenavoli L., Dallio M., Federico A., Germani G., Gitto S., Leandro G., Loguercio C., Marra F., Stasi E. Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) Dig. Liver Dis. 2020;52:374–391. doi: 10.1016/j.dld.2019.12.008. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical